Zai Lab (ZLAB) Scheduled to Post Quarterly Earnings on Tuesday

Zai Lab (NASDAQ:ZLAB - Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect Zai Lab to post earnings of ($0.71) per share for the quarter. Parties that wish to listen to the company's conference call can do so using this link.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.16). Zai Lab had a negative return on equity of 37.96% and a negative net margin of 92.44%. The business had revenue of $100.50 million during the quarter, compared to analyst estimates of $94.46 million. On average, analysts expect Zai Lab to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zai Lab Trading Up 0.1 %

NASDAQ ZLAB traded up $0.03 during trading hours on Tuesday, reaching $30.92. 598,878 shares of the company traded hands, compared to its average volume of 664,211. The stock has a market capitalization of $3.08 billion, a PE ratio of -10.06 and a beta of 1.04. Zai Lab has a 12 month low of $13.48 and a 12 month high of $36.60. The company has a 50 day moving average of $24.26 and a two-hundred day moving average of $20.24.

Insiders Place Their Bets

In other Zai Lab news, insider Joshua L. Smiley sold 4,352 shares of Zai Lab stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $16.67, for a total transaction of $72,547.84. Following the transaction, the insider now directly owns 43,232 shares in the company, valued at approximately $720,677.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 13.88% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zai Lab in a research note on Friday, October 25th. JPMorgan Chase & Co. increased their target price on Zai Lab from $38.00 to $44.00 and gave the stock an "overweight" rating in a research report on Monday, October 21st.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.